You are here: Home

GSK

15.04.2014

GSK Faces Criminal Bribery Investigation in Poland

GlaxoSmithKline (GSK) is facing fresh allegations of corruption, following reported incidents in China and Iraq. Polish authorities have launched a criminal investigation against the UK's biggest drugmaker for allegedly bribing doctors to promote its lung drug Seretide, also known as Advair, which has worldwide sales of around $8 billion a year. more
11.04.2014

Amgen Ends Non-U.S. Co-Marketing Pact With GSK

U.S. biotechnology firm Amgen, the world's largest, is ending its  agreement with the U.K. drugmaker GlaxoSmithkline for the marketing of its osteoporosis drug in some regions outside the U.S.. more
10.04.2014

GlaxoSmithKine Investigates Alleged Bribery in Iraq

U.K. drugmaker GlaxoSmithKine (GSK), already facing corruption accusations in China, is now investigating allegations of bribery in Iraq, the company has confirmed. The latest controversy involves claims that GSK hired Iraqi government-employed physicians and pharmacists as paid sales representatives to improperly boost use of its products. more
28.03.2014

GSK Combined Melanoma Treatment Delayed in Europe

GlaxoSmithKline (GSK), the UK's largest pharmaceutical company, has provisionally withdrawn its marketing authorization application to the European Medicines Agency (EMA) for the combined use of Tafinlar (also known as dabrafenib, Mekinist, or trametinib). more
12.03.2014

GlaxoSmithKline Offer lifts Indian Stakeholding to 75%

British drugmaker GlaxoSmithKline (GSK) said it has successfully increased its stake in its publicly-listed Indian pharmaceuticals subsidiary GlaxoSmithKline Pharmaceuticals Limited from 50.7% to 75%. The Indian firm will remain publicly-listed. more
19.12.2013

Facing Fines, Glaxo SmithKline to Stop Drug Promotion Excesses

UK drugmaker Glaxo SmithKline has said it would cease offering financial incentives to doctors to promote its products through speaking engagements, for example. The company also will stop linking remuneration of its sales representatives to the number of prescriptions generated. Starting from the beginning of 2015 it also will no longer pay healthcare professionals to attend medical conferences. more
03.12.2013

Cameron Raises GSK’s Problems as CEO Joins Him On China Visit

British Prime Minister David Cameron raised GlaxoSmithKline's problems in China - where it is being investigated for alleged bribery - with political leaders on Monday as the drugmaker emphasized its commitment to doing business there. more
27.11.2013

Glaxo SmithKline to Invest in Scottish Plant expansion

Glaxo SmithKline (GSK) has announced plans to invest £25 million in expanding its active ingredient formulating plant at Montrose, Scotland. The UK drug maker said it would locate production of four unspecified new entities at the site, where it is receiving more than £3 million in financial support from the local government of Angus and the business development agency Scottish Enterprise. more
25.04.2013

GSK Puts Lucozade and Ribena Drink Brands up for Sale

GlaxoSmithKline is to sell soft drink brands Lucozade and Ribena in a move analysts believe will raise over 1 billion pounds ($1.5 billion) and focus its consumer health business on global products. The plan was announced on Wednesday alongside first-quarter results that saw sales at Britain's biggest drugmaker drop a slightly smaller-than-expected 3% from a year ago. more
19.04.2013

UK Watchdog Accuses GSK Over 'Pay-for-delay' Drug Deals

Britain's competition body accused GlaxoSmithKline of market abuse for striking deals with three generic drugmakers that paid them to delay launching cheap copies of its antidepressant Seroxat. GSK, Britain's biggest drugmaker, said it believed it had acted lawfully. If it is found to have broken the law, it could be fined up to 10% of its worldwide turnover, which amounted to 26.4 billion pounds ($40.4 billion) in 2012. more
RSS Newsletter